Outlook Therapeutics Files 10-K/A Amendment

TL;DR

Outlook Therapeutics filed an amended 10-K for FY24, check for updates.

AI Summary

Outlook Therapeutics, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended September 30, 2024. The company, formerly known as Oncobiologics, Inc., is incorporated in Delaware and headquartered in Iselin, New Jersey. This filing provides updated information regarding the company's operations and financial status.

Why It Matters

This amendment to the annual report provides updated disclosures for investors and stakeholders regarding Outlook Therapeutics' financial performance and business operations for the fiscal year ending September 30, 2024.

Risk Assessment

Risk Level: medium — As a 10-K/A filing, it indicates a correction or addition to a previously filed report, suggesting potential issues or a need for clarification that could impact investor understanding.

Key Numbers

• 0930 — Fiscal Year End (Indicates the end of the reporting period for the annual report.)

Key Players & Entities

• Outlook Therapeutics, Inc. (company) — Registrant
• Oncobiologics, Inc. (company) — Former company name
• September 30, 2024 (date) — Fiscal year end
• Iselin, New Jersey (location) — Principal executive offices
• 001-37759 (other) — SEC File Number

FAQ

Key Financial Figures

• $0.01 — 0,072 shares of common stock, par value $0.01 per share. Auditor Firm ID: 185 Audito

Filing Documents

• otlk-20240930x10ka.htm (10-K/A) — 621KB
• otlk-20240930xex31d2.htm (EX-31.2) — 7KB
• 0001558370-25-000366.txt ( ) — 864KB
• otlk-20240930.xsd (EX-101.SCH) — 3KB
• otlk-20240930_lab.xml (EX-101.LAB) — 24KB
• otlk-20240930_pre.xml (EX-101.PRE) — 15KB
• otlk-20240930x10ka_htm.xml (XML) — 8KB

Executive Compensation

Executive Compensation 6 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 15 Item 13. Certain Relationships and Related Transactions, and Director Independence 18 Item 14. Principal Accountant Fees and Services 20 PART IV. Item 15. Exhibits and Financial Statement Schedules 21 Item 16. Form 10-K Summary 24

Signatures

Signatures 25 1 Table of Contents PART III

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE Directors and Executive Officers The following table sets forth information concerning our current executive officers and directors as of January 15, 2025. There are no family relationships among any of our directors or executive officers. NAME AGE POSITION HELD WITH THE COMPANY Executive Officers Lawrence A. Kenyon 59 Interim Chief Executive Officer, Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Director Jeff Evanson 56 Chief Commercial Officer Non-Employee Directors Ralph H. "Randy" Thurman 75 Executive Chairman of the Board, Director Gerd Auffarth 60 Director Julian Gangolli 67 Director Yezan Haddadin 49 Director Julia A. Haller 70 Director Kurt J. Hilzinger 64 Director Andong Huang 27 Director Faisal G. Sukhtian 40 Director Executive Officers Lawrence A. Kenyon . Mr. Kenyon has served as our Interim Chief Executive Officer since December 2024, a member of our Board since August 2018, as Chief Executive Officer and President from August 2018 to July 2021, as Interim Chief Executive Officer from June 2018 to August 2018, and as our Chief Financial Officer, Treasurer and Corporate Secretary since September 2015. Prior to that, from February 2014 to September 2015, Mr. Kenyon served as the Chief Financial Officer of Arno Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics for cancer and other life-threatening diseases, and also as Chief Operating Officer from July 2014 to September 2015. From December 2011 to March 2013, Mr. Kenyon served as the Interim President & Chief Executive Officer, Chief Financial Officer and Secretary of Tamir Biotechnology, Inc., a publicly held biopharmaceutical company engaged in the development of oncology and anti-infective therapeutics. Prior to that, from December 2008 to July 2010, Mr. Kenyon was the Executive Vice President, Finance and, commencing in Ma

EXECUTIVE COMPENSATION

ITEM 11. EXECUTIVE COMPENSATION

Executive Compensation

Executive Compensation For the year ended September 30, 2024, our named executive officers are: Lawrence A. Kenyon , our Chief Financial Officer and Interim Chief Executive Officer; Jeff Evanson, our Chief Commercial Officer; and C. Russell Trenary III , our former President and Chief Executive Officer. As previously disclosed, on December 3, 2024, Mr. Trenary stepped down as President and Chief Executive Officer of the Company and as a member of the Board, and Mr. Kenyon was appointed to serve as Interim Chief Executive Officer. Mr. Kenyon also continues to serve as Chief Financial Officer of the Company. Summary Compensation Table The following table sets forth the information as to compensation awarded to, paid to or earned by our named executive officers. We did not pay any non-equity incentive plan compensation or have any non-qualified deferred compensation earnings and have omitted those columns from the table. On March 14, 2024, we effected a reverse stock split, or the Reverse Split. All equity-related information presented in the footnotes below gives retroactive effect to the Reverse Split. All Other Salary Bonus Option Awards Compensation Total Name and Principal Position Year ($) ($) ($) (1) ($) (2) ($) Lawrence A. Kenyon (3) 2024 475,000 — 158,427 1,170 634,597 Chief Financial Officer and Interim Chief Executive Officer Jeff Evanson 2024 450,000 — 316,859 1,170 768,029 Chief Commercial Officer 2023 450,000 — 267,025 1,170 718,195 C. Russell Trenary III (4) 2024 600,000 — 5,766,842 11,111 6,377,953 Former President and Chief Executive Officer 2023 600,000 — 1,147,963 10,899 1,758,862 (1) In accordance with SEC rules, this column reflects the aggregate grant date fair value of the stock option awards granted computed in accordance with ASC 718, for stock-based compensation transactions. These amounts do not reflect the actual economic value that would be realized

View Full Filing

View this 10-K/A filing on SEC EDGAR